EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Evolus, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $294.96M | $264.31M | $199.72M | $146.59M | $98.97M | $55.80M | $34.24M | $0 | 99.3% | +11.6% |
| Service revenue | $2.22M | $1.97M | $2.36M | $2.02M | $702.00K | $738.00K | $688.00K | $0 | 0.7% | +12.8% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | $253.16M | $195.42M | $146.15M | – | – | – | – | – | – |
| International | – | $13.12M | $6.66M | $2.47M | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Evolus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.